Research programme: antibody drug conjugates - Califia Pharma/Lantern Pharma
Alternative Names: LP-A18Latest Information Update: 28 Feb 2025
At a glance
- Originator Califia Pharma; Lantern Pharma
- Class Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Solid tumours
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 28 Feb 2025 No recent reports of development identified for research development in Solid-tumours in USA (Parenteral)
- 01 Nov 2021 Lantern Pharma plans IND-enabling studies for Solid tumours and Cancer